Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer

ABSTRACT Mutation of the tumor suppressor gene TP53 promotes ovarian cancer progression and therapeutic resistance. Whether mutant p53 (mtp53) regulates alternative splicing and how this regulation can be exploited for cancer therapy remain unclear. Here, small nuclear ribonucleoprotein D2 polypepti...

Descrición completa

Detalles Bibliográficos

Principais autores:	Wei Zhao, Qian Hao, Yu Gan, Jing Tong, Xiaodan Chen, Shuran Tan, Ruiwen Ruan, Yingdan Huang, Mingming Cao, Jun Deng, Tao Han, Getao Shi, Bo Gao, Yu Zhang, Xiang Zhou
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2026-03-01
Series:	Advanced Science
Assuntos:	alternative splicing engineered exosomes p53 SNRPD2 targeted therapy
Acceso en liña:	https://doi.org/10.1002/advs.202513369
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!